Both Novo Nord's Dual GIP/GLP-1 and Semaglutide are new medications intended for addressing type 2 diabetes and supporting slimming. However, they operate through varied processes . Wegovy is a GLP-1 receptor activator , while Retatrutide acts as a dual GIP and GLP-1 stimulator, possibly offering a more significant impact on combined glucose contro